UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine in Houston have completed an early phase clinical trial showcasing the successful use of CAR-T therapy to treat Hodgkin lymphoma successfully for the first time. A powerful immuno-oncology approach that uses a patient’s reprogrammed immune cells, the results have been peer reviewed and published in the Journal of Clinical Oncology.
The Condition and the Breakthrough
Relapsed Hodgkin lymphoma patients often don’t respond well to other therapies, reported Barbara Savoldo, MD, PhD, professor in the UNC Department of Microbiology and Immunology at the UNC School of Medicine. Dr. Savoldo and team have been investigating the use of CAR-T cells targeting Hodgkin lymphoma in the past few years. Hodgkin lymphoma is a type of lymphoma in which cancer originates from a specific type of white blood cell called lymphocytes. Considered rare with less than 200,000 cases per year, according to the National Cancer Institute (NCI) an estimated 8,480 new cases will occur in 2020 with 970 deaths.
Approximately 85 percent of patients are either cured or can benefit from a significant overall survival after chemotherapy...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).